These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6747817)

  • 1. Pharmacokinetics of quinidine and three of its metabolites in man.
    Rakhit A; Holford NH; Guentert TW; Maloney K; Riegelman S
    J Pharmacokinet Biopharm; 1984 Feb; 12(1):1-21. PubMed ID: 6747817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.
    Guentert TW; Holford NH; Coates PE; Upton RA; Riegelman S
    J Pharmacokinet Biopharm; 1979 Aug; 7(4):315-30. PubMed ID: 512840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs.
    Rakhit A; Holford NH; Effeney DJ; Riegelman S
    J Pharmacokinet Biopharm; 1984 Oct; 12(5):495-515. PubMed ID: 6520745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition kinetics of quinidine.
    Ueda CT; Hirschfeld DS; Scheinman MM; Rowland M; Williamson BJ; Dzindzio BS
    Clin Pharmacol Ther; 1976 Jan; 19(1):30-6. PubMed ID: 1245091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics and dynamics of quinidine-N-oxide in healthy subjects.
    Ha HR; Vozeh S; Uematsu T; Guentert TW; Follath F
    Clin Pharmacol Ther; 1987 Sep; 42(3):341-5. PubMed ID: 3621790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absolute quinidine bioavailability.
    Ueda CT; Williamson BJ; Dzindzio BS
    Clin Pharmacol Ther; 1976 Sep; 20(3):260-5. PubMed ID: 954347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.
    Jaillon P; Poirier JM; Lecocq B; Jarreau C; Pays M; Richard MO; Cheymol G
    Eur J Drug Metab Pharmacokinet; 1986; 11(3):233-8. PubMed ID: 3816879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-time effects of quinidine disposition kinetics in rhesus monkeys.
    Ueda CT; Ballard B; Rowland M
    J Pharmacol Exp Ther; 1977 Mar; 200(3):459-68. PubMed ID: 403278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of quinidine and its metabolite, quinidine-N-oxide, in beagle dogs.
    Rakhit A; Guentert TW; Holford NH; Verhoeven J; Riegelman S
    Eur J Drug Metab Pharmacokinet; 1984; 9(4):315-24. PubMed ID: 6532805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic studies of quinidine in patients with arrhythmias.
    Conrad KA; Molk BL; Chidsey CA
    Circulation; 1977 Jan; 55(1):1-7. PubMed ID: 830196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance.
    Hardy BG; Schentag JJ
    Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):388-91. PubMed ID: 3220613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition kinetics of two oral forms of quinidine.
    Mahon WA; Mayersohn M; Inaba T
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):566-75. PubMed ID: 1277713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of quinidine.
    Ochs HR; Greenblatt DJ; Woo E
    Clin Pharmacokinet; 1980; 5(2):150-68. PubMed ID: 6988137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration.
    Fleuren HL; Thien TA; Verwey-van Wissen CP; van Rossum JM
    Eur J Clin Pharmacol; 1979 Feb; 15(1):35-50. PubMed ID: 421727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects.
    Vozeh S; Uematsu T; Guentert TW; Ha HR; Follath F
    Clin Pharmacol Ther; 1985 May; 37(5):575-81. PubMed ID: 3987181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.
    Ueda CT; Dzindzio BS
    Eur J Clin Pharmacol; 1979 Sep; 16(2):101-5. PubMed ID: 499305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients.
    Edwards DJ; Axelson JE; Visco JP; vanEvery S; Slaughter RL; Lalka D
    Br J Clin Pharmacol; 1987 Mar; 23(3):351-4. PubMed ID: 3567051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
    Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impairment of digoxin clearance by coadministration of quinidine.
    Ochs HR; Bodem G; Greenblatt DJ
    J Clin Pharmacol; 1981 Oct; 21(10):396-400. PubMed ID: 7309901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.